（文章来源：每日经济新闻） 联化科技（002250.SZ）11月24日在投资者互动平台表示，您好，公司根据客户要求的配方配置电解 液，其中如涉及LiFSI以自产为主，如涉及六氟磷酸锂以外购为主。谢谢！ 每经AI快讯，有投资者在投资者互动平台提问：请问贵司临海基地10万吨电解液是什么种类的电解 液？是否包含2万吨六氟磷酸锂和1万吨双氟磺亚酰胺锂？ ...

Core Insights - The pharmaceutical MNC supply chain has extremely high entry barriers, requiring years for supplier certification through cross-departmental audits in technology, quality, EHS, and compliance. Once included in the qualified supplier list, a strong lock-in effect is formed, making it difficult for new entrants to disrupt the existing supply structure even if they meet technical standards, thus demonstrating a strong first-mover advantage [4][7]. - MNCs demand far more than conventional quality compliance, emphasizing full-process controllability and risk management capabilities. Compliance with guidelines such as EU GMP and ICHQ is required, along with the establishment of traceability systems and safety stock. Any process changes or relocation of production sites must undergo strict and time-consuming certification [4][7]. - In procurement decisions, MNCs are relatively insensitive to price factors, prioritizing the integrity of the supply chain over cost. For MNCs, API costs represent only a small portion of their terminal formulation sales, leading them to pay a premium for stable, traceable, and zero major quality incident supply capabilities, viewing supply chain resilience as a core competitive advantage rather than a cost item. Thus, entering the MNC supply chain often means effectively avoiding "price internalization" [4][7]. - Investment recommendations include innovative drug and device companies such as Furuya Co., Aonlikang, Shutaishen, Weichuang Bio, and others. From the perspective of CXO and raw materials, companies like WuXi AppTec, Jiuzhou Pharmaceutical, Chengda Pharmaceutical, and others are suggested for attention [4][7]. Market Performance Overview - As of November 21, 2025, the TTM-PE of the pharmaceutical and biotechnology industry is 48.84 times, which is 100% higher than the historical lowest PE valuation of 24.38 times on January 3, 2019. The premium rate relative to the CSI 300 is 252%, exceeding the historical lowest valuation premium of 124% on February 6, 2018, by 128 percentage points, and is 11 percentage points higher than the average valuation premium rate of 241% over the past decade [8][12]. - From November 17 to November 21, 2025, the pharmaceutical and biotechnology sector experienced a decline of 6.88%, ranking 22nd among 27 sub-industries. The chemical raw materials sector saw the largest decline at -8.60% [12][15]. Industry Dynamics - Pfizer's Class 1 new drug, Matacizumab, was approved for marketing on November 21, 2025, for the routine prevention and treatment of bleeding in patients with severe hemophilia A or B [20]. - Boehringer Ingelheim's Class 1 new drug, BI764198, was proposed for inclusion as a breakthrough therapy on November 18, 2025, targeting primary focal segmental glomerulosclerosis [21]. - The PD-1 inhibitor H drug, Surulutumab, developed by Fuhong Hanlin, was officially included as a breakthrough therapy on November 20, 2025, for gastric cancer treatment [22]. - On November 17, 2025, FDA approved the biosimilar of Tysabri, developed by Sandoz, for multiple sclerosis and Crohn's disease [23].

Core Viewpoint - The company is currently focused on the sales of LiFSI and electrolyte products, while the lithium hexafluorophosphate project is still in the technical improvement stage. The company's new energy business revenue is expected to achieve a breakthrough by 2025 [1] Group 1 - The company primarily sells LiFSI and electrolyte products [1] - The lithium hexafluorophosphate project is undergoing technical improvements [1] - The new energy business revenue is projected to significantly increase by 2025 [1]

格隆汇11月24日丨联化科技(002250.SZ)在投资者互动平台表示，公司目前以销售LiFSI和电解液产品为 主。 ...

Investment Rating - The report maintains a recommendation for the organic silicon industry, highlighting its potential benefits from the chemical sector's internal competition [4]. Core Viewpoints - The chemical sector experienced a decline of 7.47% in the third week of November, underperforming the Shanghai Composite Index by 3.58 percentage points [13]. - The only sub-industry that saw an increase was petroleum processing, which rose by 2.64%, while 31 sub-industries declined, with the largest drop in acrylic fiber at -15.33% [17]. - Key products with significant price increases included dimethyl carbonate (+12.32%) and thionyl chloride (+11.39%), while liquid chlorine saw the largest decrease at -6.25% [22][3]. - The report suggests focusing on leading companies that benefit from the chemical sector's internal competition, such as Xin'an Chemical, Xingfa Group, and Baofeng Energy [4]. Industry Performance - The chemical sector's dynamic PE ratio stands at 23.78, significantly higher than the average PE of 5.33 since 2015 [13]. - The total number of stocks in the industry is 446, with a total market value of 7114.2 billion and a circulating market value of 6648.5 billion [5]. Price and Spread Trends - The report lists the top five products with the highest price increases and decreases, indicating significant volatility in the market [22][3]. - The price spread for propylene (methanol-based) increased by 296.55%, while the PTA spread decreased by 157.04% [42][46]. Inventory Changes - Notable inventory changes include a decrease in stocks of chlorpyrifos (-12.5%) and propylene oxide (-11.83%), while polyester filament saw an increase of 10.21% [66].

Core Viewpoint - Lianhua Technology's stock has experienced significant fluctuations, with a year-to-date increase of 111.29% but a recent decline of 22.67% over the past five trading days [1] Group 1: Stock Performance - As of November 24, Lianhua Technology's stock price is 11.60 CNY per share, with a market capitalization of 10.439 billion CNY [1] - The stock has seen a trading volume of 2.68 billion CNY and a turnover rate of 2.53% [1] - The company has appeared on the "Dragon and Tiger List" 10 times this year, with the latest appearance on November 14, where it recorded a net purchase of 124 million CNY [1] Group 2: Business Overview - Lianhua Technology, established on September 14, 1998, and listed on June 19, 2008, operates in three main sectors: pesticides, pharmaceuticals, and functional chemicals [2] - The revenue composition is as follows: pesticides 54.03%, pharmaceuticals 32.32%, functional chemicals 8.42%, equipment and engineering services 4.88%, and others 0.36% [2] - The company is categorized under the basic chemicals industry, specifically in agricultural chemical products [2] Group 3: Financial Performance - For the period from January to September 2025, Lianhua Technology achieved a revenue of 4.718 billion CNY, representing a year-on-year growth of 8.25% [2] - The net profit attributable to shareholders for the same period was 316 million CNY, showing a remarkable increase of 871.65% [2] - The company has distributed a total of 960 million CNY in dividends since its A-share listing, with 129 million CNY distributed in the last three years [3]

Summary of Conference Call Notes Industry Overview - **Global Market Trends**: Recent adjustments in global risk assets, particularly in US stocks and Bitcoin, with significant declines noted. The Shanghai Composite Index fell below its upward trend line, but the Federal Reserve's signals of easing have reduced the risk of further declines in the short term [3][1]. Key Points by Industry Transportation Sector - **Impact of Japan-China Relations**: The transportation sector faced challenges due to reduced flights on Japan-China routes. However, the three major airlines were minimally affected as this route only accounts for a small percentage of their total flights. Spring Airlines and Juneyao Airlines experienced larger adjustments, while Huaxia Airlines remained unaffected [5][1]. Express Delivery Industry - **October Data and Financial Performance**: The express delivery sector showed positive trends with October data and ZTO's Q3 financial report. YTO Express had the fastest growth rate at 13%, while Shentong Express grew by over 4%, and Yunda Express saw a decline of 5%. The overall outlook for the sector remains optimistic, with expectations of continued growth into Q1 2026 [6][1]. Shipping Industry - **Freight Rates and Future Outlook**: The shipping sector saw freight rates reach multi-year highs before a slight correction. The peak season may last longer than expected, with further potential for rate increases. Key companies to watch include China Merchants Energy Shipping and Hainan Airlines [7][8]. Chemical Industry - **Current Market Conditions**: The CCPI index remained stable, while crude oil prices fell, leading to a decline in the chemical output index. The fourth quarter is typically a demand lull, with price sustainability needing validation in Q1 2026. Key sub-sectors include polyester filament and viscose staple fiber, with specific companies recommended for investment [11][12][17]. Lithium and Battery Materials - **Price Increases and Demand**: Lithium hexafluorophosphate prices surged to 167,000 CNY/ton, with significant increases in electrolyte and additive prices. The demand for energy storage is expected to drive profitability, with a recovery anticipated in 2026. Recommended companies include Sinoma Technology and Lianhua Technology [14][12]. Coal Industry - **Market Performance and Future Expectations**: The coal sector experienced a significant drop of 5.67%, with some companies like China Shenhua showing resilience. Despite short-term declines, the long-term fundamentals remain unchanged, and there are opportunities in quality stocks [21][22]. Organic Silicon and Soda Ash - **Market Dynamics**: The organic silicon industry reached a consensus on production cuts, with prices rising. The soda ash market saw price increases following production halts. Both sectors are expected to improve significantly by 2026, with key companies highlighted for investment [16][12]. Additional Insights - **Investor Confidence**: Jitu International's management has been actively repurchasing shares to bolster investor confidence, particularly in Southeast Asia and emerging markets [9][10]. - **Investment Recommendations**: The call emphasized focusing on high dividend-paying coal companies and other resilient sectors, suggesting a strategic approach to navigating potential market fluctuations [25][10]. This summary encapsulates the key insights and recommendations from the conference call, providing a comprehensive overview of the current market landscape across various industries.

Market Overview - The agricultural chemical sector experienced a decline of 5.39% on November 21, with Chengxing Co. leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Individual Stock Performance - Chengxing Co. (600078) closed at 11.42, down 10.01% with a trading volume of 815,900 shares [1] - Lianhua Technology (002250) closed at 11.84, down 9.96% with a trading volume of 846,200 shares [1] - Bluefeng Biochemical (002513) closed at 8.05, down 9.96% with a trading volume of 438,000 shares [1] - Liuguo Chemical (600470) closed at 6.09, down 9.78% with a trading volume of 362,100 shares [1] - Chuanjinno (300505) closed at 21.57, down 8.33% with a trading volume of 246,600 shares [1] - Hebang Bio (603077) closed at 2.13, down 7.79% with a trading volume of 3,585,900 shares [1] - Chuanheng Co. (002895) closed at 34.45, down 7.64% with a trading volume of 216,400 shares [1] - Hongda Co. (600331) closed at 11.05, down 7.61% with a trading volume of 1,041,300 shares [1] - Yantu Holdings (002539) closed at 11.03, down 7.47% with a trading volume of 475,800 shares [1] - Salt Lake Co. (000792) closed at 26.04, down 7.20% with a trading volume of 2,051,800 shares [1] Capital Flow Analysis - The agricultural chemical sector saw a net outflow of 1.435 billion yuan from institutional investors, while retail investors had a net inflow of 1.383 billion yuan [1] - The table of capital flow for individual stocks indicates varying levels of net inflow and outflow among different companies [2] Individual Stock Capital Flow - Hongda Co. (600331) had a net inflow of 56.76 million yuan from institutional investors, but a net outflow from retail investors [2] - Guangxin Co. (603599) saw a net inflow of 27.20 million yuan from institutional investors, with a net outflow from retail investors [2] - Zhongqi Co. (300575) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow from retail investors [2] - Andamite A (000553) experienced a net inflow of 15.01 million yuan from institutional investors, but a significant net outflow from retail investors [2] - Sichuan Meifeng (000731) had a net inflow of 13.36 million yuan from institutional investors, with a net outflow from retail investors [2]

Core Viewpoint - Lianhe Technology reported strong financial performance for the first three quarters of 2025, with significant increases in net profit and operating income, indicating improved profitability and market expectations being exceeded [1][4]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 4.718 billion yuan, a year-on-year increase of 8.25% [1]. - The net profit attributable to shareholders reached 316 million yuan, up 871.65% year-on-year, while the net profit excluding non-recurring items was 300 million yuan, reflecting a substantial increase of 1504.44% [1]. - In Q3 2025, the company reported operating income of 1.569 billion yuan, a quarter-on-quarter decrease of 4.34%, and a net profit of 92 million yuan, down 47.26% from the previous quarter [1]. Cost Management - Sales expenses decreased by 1.12% year-on-year, with a sales expense ratio of 0.47%, down 0.04 percentage points [2]. - Financial expenses saw a significant decline of 153.55%, resulting in a negative financial expense ratio of -0.61%, down 1.85 percentage points [2]. - Management expenses fell by 1.96%, with a management expense ratio of 10.83%, down 1.13 percentage points [2]. - R&D expenses increased by 11.06%, with a ratio of 5.06%, up 0.13 percentage points [2]. Cash Flow and Working Capital - Operating cash flow for the first three quarters was 917 million yuan, a slight decrease of 0.60% year-on-year [2]. - Investment cash flow was -246 million yuan, an increase of 48.23% year-on-year [2]. - Financing cash flow was -751 million yuan, a dramatic decline of 1122.11% year-on-year [2]. - The ending cash and cash equivalents balance was 908 million yuan, down 17.86% year-on-year [2]. - Accounts receivable increased by 58.38%, with a turnover rate dropping from 4.01 times to 3.25 times year-on-year [2]. - Inventory rose by 6.04%, with a turnover rate improving from 1.38 times to 1.44 times year-on-year [2]. New Energy Business Development - The company is making progress in its new energy business, focusing on electrolyte products and gradually entering the new energy sector [3]. - The company has achieved stable supply and increasing production of electrolyte products, with plans for further commercialization of related products [3]. - Revenue from the new energy business is expected to break through in 2025, contributing positively to overall performance [3]. Future Outlook - Revenue projections for Lianhe Technology from 2025 to 2027 are 6.882 billion yuan, 7.949 billion yuan, and 9.029 billion yuan, representing year-on-year growth rates of 21.2%, 15.5%, and 13.6% respectively [4]. - Net profit forecasts for the same period are 409 million yuan, 581 million yuan, and 727 million yuan, with growth rates of 296.7%, 41.9%, and 25.3% respectively [4]. - The company maintains a "buy" rating based on the expected profitability from its new energy product segment [4].

Group 1 - The enthusiasm for stock buybacks among A-share listed companies has significantly increased this year, with a total buyback amount reaching 155.88 billion yuan, marking a five-year high [1] - As of November 19, 462 A-share listed companies have announced 509 buyback plans this year, with 128 plans aimed at reducing registered capital, representing 25.14%, an increase from 17.36% in the same period last year [1] - Major companies like CATL and Midea Group have announced substantial buyback plans, indicating a trend of normalizing buybacks as a key measure for market value management [2][3] Group 2 - The proportion of cancellation buybacks is steadily increasing, which is seen as a way to enhance earnings per share and boost market confidence [4] - Recent examples include Yabao Pharmaceutical completing a buyback of 8 million shares at an average price of 6.52 yuan per share, totaling 52.15 million yuan [4] - Experts suggest that the increase in cancellation buybacks is supported by improved profitability and liquidity of listed companies [4] Group 3 - Recommendations to enhance the proportion of cancellation buybacks include regulatory guidance, tax incentives, and improving the process for canceling shares [5] - There is a call for better market awareness and understanding of the value of cancellation buybacks [5]